Crescita Therapeutics Inc.
CTX.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.10% | 9.09% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.10% | 9.09% | |||
| Cost of Revenue | -8.33% | 27.41% | |||
| Gross Profit | -1.17% | -7.19% | |||
| SG&A Expenses | 8.32% | 28.81% | |||
| Depreciation & Amortization | 155.22% | -191.07% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.26% | 12.68% | |||
| Operating Income | -217.05% | -132.40% | |||
| Income Before Tax | -65.66% | -192.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -63.55% | -193.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -63.55% | -193.29% | |||
| EBIT | -217.05% | -132.40% | |||
| EBITDA | -616.44% | -150.93% | |||
| EPS Basic | -63.50% | -194.48% | |||
| Normalized Basic EPS | -3,011.11% | -103.61% | |||
| EPS Diluted | -63.50% | -194.48% | |||
| Normalized Diluted EPS | -3,011.11% | -103.61% | |||
| Average Basic Shares Outstanding | 0.00% | -1.18% | |||
| Average Diluted Shares Outstanding | 0.00% | -1.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||